AU6294700A - Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines - Google Patents

Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines

Info

Publication number
AU6294700A
AU6294700A AU62947/00A AU6294700A AU6294700A AU 6294700 A AU6294700 A AU 6294700A AU 62947/00 A AU62947/00 A AU 62947/00A AU 6294700 A AU6294700 A AU 6294700A AU 6294700 A AU6294700 A AU 6294700A
Authority
AU
Australia
Prior art keywords
medicines
growth factors
fibroblast growth
idiotypic antibodies
idiotypic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62947/00A
Inventor
Jacqueline Jouanneau
Bernard Andre Malavaud
Jean Plouet
Pierre Savagner
Sylvie Sordello
Jean-Paul Thiery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU6294700A publication Critical patent/AU6294700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU62947/00A 1999-07-07 2000-07-06 Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines Abandoned AU6294700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9908779A FR2796073B1 (en) 1999-07-07 1999-07-07 ANTI-IDIOTYPIC ANTIBODIES FOR FIBROBLAST GROWTH FACTORS AND THEIR USE AS MEDICAMENTS
FR99/08779 1999-07-07
PCT/FR2000/001952 WO2001004160A1 (en) 1999-07-07 2000-07-06 Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines

Publications (1)

Publication Number Publication Date
AU6294700A true AU6294700A (en) 2001-01-30

Family

ID=9547809

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62947/00A Abandoned AU6294700A (en) 1999-07-07 2000-07-06 Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines

Country Status (6)

Country Link
EP (1) EP1189947A1 (en)
JP (1) JP2003504379A (en)
AU (1) AU6294700A (en)
CA (1) CA2378451A1 (en)
FR (1) FR2796073B1 (en)
WO (1) WO2001004160A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332761A1 (en) * 2002-01-31 2003-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Agonists of fibroblast growth factor receptors (FGFR)
ES2363765T3 (en) 2002-01-31 2011-08-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR AGONISTS.
US20040048319A1 (en) * 2002-05-03 2004-03-11 Mather Jennie P. ALCAM and ALCAM modulators
AU2003265057A1 (en) * 2002-09-04 2004-03-29 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
FR2845691B1 (en) * 2002-10-10 2004-12-10 Centre Nat Rech Scient NOVEL ENDOTHELIAL CELLS, ANTIBODIES DIRECTED AGAINST THESE CELLS AND THEIR USE, IN PARTICULAR FOR SCREENING ANGIOGENESIS-INHIBITING SUBSTANCES
FR2858326A1 (en) * 2003-08-01 2005-02-04 Abtech Preparing antibodies that mimic a selected substance, useful particularly for activating or inhibiting biological processes, e.g. for inhibiting angiogenesis, comprises series of three immunizations
US7872016B2 (en) 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
AR090017A1 (en) * 2011-05-16 2014-10-15 Genentech Inc FGFR1 AGONISTS AND THEIR METHODS OF USE
TWI728373B (en) 2013-12-23 2021-05-21 美商建南德克公司 Antibodies and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742662B1 (en) * 1995-12-21 1998-01-23 Centre Nat Rech Scient ANTI-IDIOTYPIC ANTIBODIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND THEIR USE AS MEDICAMENTS
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
WO1999045018A1 (en) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens

Also Published As

Publication number Publication date
CA2378451A1 (en) 2001-01-18
JP2003504379A (en) 2003-02-04
WO2001004160A1 (en) 2001-01-18
EP1189947A1 (en) 2002-03-27
FR2796073A1 (en) 2001-01-12
FR2796073B1 (en) 2003-08-29

Similar Documents

Publication Publication Date Title
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU4055600A (en) Impaction substrate and methods of use
AU5440901A (en) Cosmetic and/or pharmaceutical preparations
AU4065200A (en) Zirconia sol and process of making same
AU5963900A (en) Muteins of bilin-binding protein
AU4139801A (en) Controlled delivery of antigens
AU7907300A (en) Novel combination of loteprednol and antihistamines
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU2289601A (en) The use of procyanidins in the modulation of cytokine gene expression and protein secretion
AU1403501A (en) Novel composition and use
AU6294700A (en) Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines
AU3553400A (en) Use and production of polypropylene
AU7271600A (en) Quinazolinone and azaquinazolinone derivatives
AU4218400A (en) Lyophilized solid dosage forms and methods of making
AU2438400A (en) Cosmetic and/or pharmaceutical preparations
AU4301100A (en) Isolated peptide of the horny layer and use thereof
EP1248844B8 (en) Analogs of human basic fibroblast growth factor
AU4293800A (en) Cosmetic and/or pharmaceutical preparations
AU5428700A (en) Acrylic acid derivatives, use of the same and intermediates for the preparation thereof
AU3569600A (en) Purification of biological preparations
AU5446900A (en) Novel murine and human kinases
AU7410900A (en) Alginate preparation and use of the same
AU4008500A (en) Platelet-derived growth factor related gene and protein
AU3775500A (en) Setting of gemstones
AU1894601A (en) Novel gene and use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase